What were the tax-withholding share dispositions in the Boston Scientific (BSX) Form 4?

The Form 4 lists dispositions of 199, 449, and 339 Boston Scientific common shares at $74.73 per share. These are labeled as payments of tax liability by delivering securities, indicating shares were withheld or delivered for taxes instead of being sold in a traditional open-market transaction.

Boston Scientific (BSX) EVP converts RSUs, delivers shares for tax obligations

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Boston Scientific EVP Padraig Andrew O'Connor reported multiple equity award transactions. On February 13, 14, and 16, 2026, restricted stock units covering 500, 1,190, and 905 units were exercised or converted into an equal number of Boston Scientific common shares at a stated price of $0.00 per share.

Related Form 4 entries show dispositions of 199, 449, and 339 common shares at $74.73 per share, characterized as payments of tax liability by delivering shares rather than open-market sales. Footnotes explain that each restricted stock unit represents a commitment to issue one share, generally in four equal annual installments beginning on specified February anniversaries of the grant dates.

Insider Trade Summary

2,595 shares exercised/converted

Mixed 9 txns

Insider O'Connor Padraig Andrew

Role EVP, Global Operations

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	905	$0.00	--
Exercise	Common Stock	905	$0.00	--
Tax Withholding	Common Stock	339	$74.73	$25K
Exercise	Restricted Stock Units	1,190	$0.00	--
Exercise	Common Stock	1,190	$0.00	--
Tax Withholding	Common Stock	449	$74.73	$34K
Exercise	Restricted Stock Units	500	$0.00	--
Exercise	Common Stock	500	$0.00	--
Tax Withholding	Common Stock	199	$74.73	$15K

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 6,433 shares (Direct)

Footnotes (1)

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

Form 4 Insider Transactions: What Each Field Means →

02/18/2026 - 05:58 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Connor Padraig Andrew

(Last)

(First)

(Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH

01752-1234

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Global Operations

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/13/2026		M		500	A	$0.0000⁽¹⁾	4,986	D
Common Stock	02/13/2026		F		199	D	$74.73	4,787	D
Common Stock	02/14/2026		M		1,190	A	$0.0000⁽¹⁾	5,977	D
Common Stock	02/14/2026		F		449	D	$74.73	5,528	D
Common Stock	02/16/2026		M		905	A	$0.0000⁽¹⁾	6,433	D
Common Stock	02/16/2026		F		339	D	$74.73	6,094	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	02/13/2026		M			500	⁽²⁾	02/13/2029⁽²⁾	Common Stock	500	$0.0000	1,502	D
Restricted Stock Units	⁽¹⁾	02/14/2026		M			1,190	⁽³⁾	02/14/2027⁽³⁾	Common Stock	1,190	$0.0000	1,190	D
Restricted Stock Units	⁽¹⁾	02/16/2026		M			905	⁽⁴⁾	02/16/2026⁽⁴⁾	Common Stock	905	$0.0000	0.0000	D

Explanation of Responses:

1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

2. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

3. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

4. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Boston Scientific (BSX) report for Padraig Andrew O'Connor?

Padraig Andrew O'Connor reported exercises of restricted stock units that converted into Boston Scientific common shares, plus share dispositions to cover tax obligations. The transactions occurred on February 13, 14, and 16, 2026, reflecting routine equity award activity rather than open-market buying or selling.

How many Boston Scientific (BSX) shares were acquired through RSU exercises?

The filing shows RSU exercises for 500, 1,190, and 905 units, each converting into an equal number of Boston Scientific common shares. These exercises were reported at a stated price of $0.00 per share, consistent with equity awards vesting rather than cash purchases in the open market.

What role does Padraig Andrew O'Connor hold at Boston Scientific (BSX)?

Padraig Andrew O'Connor is identified as an officer of Boston Scientific, serving as Executive Vice President, Global Operations. His Form 4 transactions reflect equity compensation activity associated with this role, including restricted stock unit conversions and related tax-withholding share dispositions.

How do the Boston Scientific (BSX) restricted stock units vest for Padraig O'Connor?

Footnotes explain each restricted stock unit represents a commitment to issue one share of common stock. Shares are scheduled to be issued in four equal annual installments, beginning on specified February anniversaries of the grant dates such as February 13, 2026, February 14, 2024, and February 16, 2023.

Did the Boston Scientific (BSX) Form 4 show open-market stock purchases or sales?

The Form 4 does not report open-market buys or sells. It shows derivative exercises or conversions of restricted stock units into common shares and dispositions coded as tax-withholding transactions, where shares are delivered to cover tax obligations on vested equity awards.